title: Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels.
abstract: OBJECTIVE
  To investigate laser photocoagulation and intravitreal bevacizumab efficacy and safety in patients with moderate-to-severe stage 3 retinopathy of prematurity (ROP), and to evaluate the effects of treatment on the development of peripheral retinal vessels.
  
  
  METHODS
  A retrospective chart review of 15 premature babies, all of whom were diagnosed with stage 3 ROP, was conducted. Patients with moderate-to-severe stage 3 ROP, thus with a vascular-active ROP, received intravitreal injections of bevacizumab (0.5 mg/0.02 ml) and laser photocoagulation, whereas those with relatively inactive ROP received laser photocoagulation only. Patients were examined 1, 2, 4, and 8 weeks after treatment, or until peripheral retinal vessel growth over the laser scar was noted.
  
  
  RESULTS
  Both eyes of 15 patients diagnosed with moderate-to-severe stage 3 ROP were evaluated. Eight patients (n=16 eyes) received intravitreal bevacizumab injection and laser photocoagulation, and seven patients (n=14 eyes) received laser photocoagulation only. During the follow-up period, regression of plus disease and peripheral retinal vessel development appeared significantly more rapidly in patients who received both intravitreal bevacizumab injection and laser photocoagulation. Peripheral retinal vessel development over the laser scar was identified 1-2 weeks after treatment. No systemic or significant ocular complications, such as vitreous hemorrhage, retinal detachment, or endophthalmitis, were noted during follow-up after treatment.
  
  
  CONCLUSIONS
  A combination of laser photocoagulation and intravitreal bevacizumab injection seems to be a safe and effective therapy in patients with moderate-to-severe stage 3 ROP, promulgating rapid development of peripheral retinal vessels.
authors.affiliation: Department of Ophthalmology, Asan Medical Center,University of Ulsan College of Medicine, 388-1 Pungnap-2dong, Songpa-gu, Seoul, Korea.
authors.forename: Joo Yong
authors.initials: JY
authors.lastname: Lee
authors.forename: Ju Byung
authors.initials: JB
authors.lastname: Chae
authors.forename: Sung Jae
authors.initials: SJ
authors.lastname: Yang
authors.forename: Young Hee
authors.initials: YH
authors.lastname: Yoon
authors.forename: June-Gone
authors.initials: JG
authors.lastname: Kim
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001724:Birth Weight; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D005865:Gestational Age; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007267:Injections; D017075:Laser Coagulation; D008297:Male; D012171:Retinal Vessels / Q000502:physiology*; D012178:Retinopathy of Prematurity / Q000145:classification / Q000503:physiopathology / Q000628:therapy*; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
references.citation: Retina. 2009 Apr;29(4):562
references.pmid: 19262431
references.citation: Br J Ophthalmol. 2006 Oct;90(10):1316-21
references.pmid: 16723358
references.citation: Arch Ophthalmol. 2005 Jul;123(7):991-9
references.pmid: 16009843
references.citation: Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3701-8
references.pmid: 20181842
references.citation: Retina. 2008 Jun;28(6):831-8
references.pmid: 18536599
references.citation: Ophthalmology. 2005 Sep;112(9):1636; author reply 1636
references.pmid: 16139670
references.citation: Br J Ophthalmol. 2008 Nov;92(11):1450-5
references.pmid: 18621796
references.citation: Retina. 2008 Mar;28(3 Suppl):S13-8
references.pmid: 18317338
references.citation: Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5177-82
references.pmid: 18708611
references.citation: Prog Retin Eye Res. 2003 Jan;22(1):1-29
references.pmid: 12597922
references.citation: Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):1061-3
references.pmid: 18320201
references.citation: Invest Ophthalmol Vis Sci. 2008 Jul;49(7):3107-14
references.pmid: 18378573
references.citation: Graefes Arch Clin Exp Ophthalmol. 2007 Nov;245(11):1727-30
references.pmid: 17690897
references.citation: Retina. 2004 Jun;24(3):368-75
references.pmid: 15187658
references.citation: Prog Retin Eye Res. 2003 Nov;22(6):721-48
references.pmid: 14575722
references.citation: Retina. 2008 Mar;28(3 Suppl):S19-25
references.pmid: 18317339
references.citation: Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2576-81
references.pmid: 8637916